Data Insights

Jaktinib hydrochloride by Suzhou Zelgen Biopharmaceutical for Alopecia Areata: Likelihood of Approval

Jaktinib hydrochloride is under clinical development by Suzhou Zelgen Biopharmaceutical and currently in Phase I for Alopecia Areata. According to...

Likelihood of Approval and Phase Transition Success Rate Model - Jaktinib Hydrochloride in Alopecia Areata

Data Insights

Jaktinib hydrochloride by Suzhou Zelgen Biopharmaceutical for Rheumatoid Arthritis: Likelihood of Approval

Jaktinib hydrochloride is under clinical development by Suzhou Zelgen Biopharmaceutical and currently in Phase II for Rheumatoid Arthritis. According to...

Likelihood of Approval and Phase Transition Success Rate Model - Jaktinib Hydrochloride in Rheumatoid Arthritis

Data Insights

Jaktinib hydrochloride by Suzhou Zelgen Biopharmaceutical for Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF): Likelihood of Approval

Jaktinib hydrochloride is under clinical development by Suzhou Zelgen Biopharmaceutical and currently in Phase III for Post-Essential Thrombocythemia Myelofibrosis (Post-ET...

Likelihood of Approval and Phase Transition Success Rate Model - Jaktinib Hydrochloride in Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF)

Data Insights

Jaktinib hydrochloride by Suzhou Zelgen Biopharmaceutical for Post-Polycythemia Vera Myelofibrosis (PPV-MF): Likelihood of Approval

Jaktinib hydrochloride is under clinical development by Suzhou Zelgen Biopharmaceutical and currently in Phase III for Post-Polycythemia Vera Myelofibrosis (PPV-MF)....

Likelihood of Approval and Phase Transition Success Rate Model - Jaktinib Hydrochloride in Post-Polycythemia Vera Myelofibrosis (PPV-MF)

Data Insights

Jaktinib hydrochloride by Suzhou Zelgen Biopharmaceutical for Ankylosing Spondylitis (Bekhterev's Disease): Likelihood of Approval

Jaktinib hydrochloride is under clinical development by Suzhou Zelgen Biopharmaceutical and currently in Phase III for Ankylosing Spondylitis (Bekhterev's Disease)....

Likelihood of Approval and Phase Transition Success Rate Model - Jaktinib Hydrochloride in Ankylosing Spondylitis (Bekhterev's Disease)

Data Insights

Jaktinib hydrochloride by Suzhou Zelgen Biopharmaceutical for Chronic Idiopathic Myelofibrosis (Primary Myelofibrosis): Likelihood of Approval

Jaktinib hydrochloride is under clinical development by Suzhou Zelgen Biopharmaceutical and currently in Phase II for Chronic Idiopathic Myelofibrosis (Primary...

Likelihood of Approval and Phase Transition Success Rate Model - Jaktinib Hydrochloride in Chronic Idiopathic Myelofibrosis (Primary Myelofibrosis)

Data Insights

Jaktinib hydrochloride by Suzhou Zelgen Biopharmaceutical for Ankylosing Spondylitis (Bekhterev's Disease): Likelihood of Approval

Jaktinib hydrochloride is under clinical development by Suzhou Zelgen Biopharmaceutical and currently in Phase III for Ankylosing Spondylitis (Bekhterev's Disease)....

Likelihood of Approval and Phase Transition Success Rate Model - Jaktinib Hydrochloride in Ankylosing Spondylitis (Bekhterev's Disease)

Data Insights

Jaktinib hydrochloride by Suzhou Zelgen Biopharmaceutical for Post-Polycythemia Vera Myelofibrosis (PPV-MF): Likelihood of Approval

Jaktinib hydrochloride is under clinical development by Suzhou Zelgen Biopharmaceutical and currently in Phase III for Post-Polycythemia Vera Myelofibrosis (PPV-MF)....

Likelihood of Approval and Phase Transition Success Rate Model - Jaktinib Hydrochloride in Post-Polycythemia Vera Myelofibrosis (PPV-MF)